Alnylam Pharmaceuticals (NASDAQ:ALNY) was the best performing large cap ($30B+) pharma or biotech in Q2, returning ~58.5% in the period. The biotech’s strong performance was helped significantly in late June when it reported strong pivotal trial results for vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy, sending shares skyrocketing. FollowingContinue Reading
Information Technology has been the best performing name among all 11 S&P 500 (SP500) sectors in the first half of 2024, but Cathie Wood’s actively managed ARK Innovation ETF (NYSEARCA:ARKK) – which aims to provide investors exposure to disruptive innovation and technology – was unable to keep up with it.Continue Reading
This week marks the last handful of trading days for the first half of 2024, as market participants watched the benchmark S&P 500 (SP500) advance 15.1% year to date. As the first half of 2024’s trading concludes, investors can look back to see the top 10 performing S&P 500 namesContinue Reading
